carlisle & Associates
generic drug updates News contact carlisle medical
news
generic drug updates
Generic Sulfamylon® Launches
Released: 02/18/2013
By: Mike Partridge, RPh

On February 2, 2013, Par Pharmaceutical received final FDA approval for and commenced shipping the generic equivalent for Mylan’s branded product, Sulfamylon® (mafenide acetate) topical solution. Sulfamylon® had estimated total U.S. annual sales of approximately $8 million.

Sulfamylon® is indicated as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.


<<Back
 
Company News Releases
Generic Drug Updates
Newsletter Subscription
Newsletter Login
 
 
 
 
 
© Copyright 2019 Carlisle Medical, Inc.
Twitter Twitter Twitter Twitter
disclaimer site map disclaimer